• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 20-F filed by Tiziana Life Sciences Ltd.

    4/30/25 5:00:03 PM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLSA alert in real time by email
    NT 20-F 1 ea0240274-nt20f_tiziana.htm NOTIFICATION OF LATE FILING

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 12b-25

     

    Commission File Number: 001-38723

     

    NOTIFICATION OF LATE FILING

     

    ☐   Form 10-K ☒   Form 20-F ☐   Form 11-K ☐   Form 10-Q
    ☐   Form 10-D ☐   Form N-SAR ☐   Form N-CSR  

     

    For Period Ended: December 31, 2024

     

    ☐   Transition Report on Form 10-K ☐   Transition Report on Form 10-Q
    ☐   Transition Report on Form 20-F ☐   Transition Report on Form N-SAR
    ☐   Transition Report on Form 11-K  

     

    For the Transition Period Ended: _______________________________________

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________________

     

    PART I

    REGISTRANT INFORMATION

     

    Full name of registrant Tiziana Life Sciences Ltd
    Former name if applicable  
    Address of principal executive office Clarendon House, 2 Church Street,
    City, state and zip code Hamilton, HM11, Bermuda

     

     

     

     

    PART II

    RULE 12b-25 (b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

     

      (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☒  (b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III

    NARRATIVE

     

    State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.

     

    The compilation, dissemination and review of the information required to be presented in the Form 20-F for the relevant fiscal year has imposed time constraints that have rendered timely filing of the Form 20-F impracticable without undue hardship and expense to the registrant. The registrant undertakes the responsibility to file such annual report no later than 15 days after its original due date.

     

    PART IV

    OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Keeren Shah   (44)   (0)20 7495 2379
    (Name)   (Area Code)   (Telephone Number)

      

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

     

    ☒  Yes   ☐   No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    ☐  Yes   ☒   No

     

    If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    -2-

     

     

    Tiziana Life Sciences, Inc.

    (Name of Registrant as Specified in Charter)

     

    Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Dated: April 30, 2025   /s/ Keeren Shah
      By: Keeren Shah
      Title: Chief Financial Officer

     

     

    -3-

     

    Get the next $TLSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TLSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

      NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced advancements in moderate Alzheimer's disease treatment, showcased in a recent feature on a national public radio station across the United States. The advancement involves the use of Tiziana's novel nasal spray, foralumab, which is designed to combat brain inflammation, marking a step forward in moderate Alzheimer's research and treatment. In the exclusive interview, Dr. Howard Weiner

      5/23/25 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

      NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the publication of a new study in the Journal of ‘Clinical Nuclear Medicine' demonstrating that intranasal administration of foralumab significantly dampened microglial activation in a 78-year old patient with moderate Alzheimer's disease (AD) treated as part of a Food and Drug Administration (FDA) expanded access program. The findings, published in the prestigious ‘Clinical Nuclear Me

      5/15/25 8:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces Purchase of Shares by Chairman

      NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 15,000 common shares at $1.55 per share, bringing his total holding to 43,252,143 common shares, which is 37.02% of issued share capital. About ForalumabForalumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intr

      5/12/25 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zacks Investment Research initiated coverage on Tiziana Life Sciences with a new price target

      Zacks Investment Research initiated coverage of Tiziana Life Sciences with a rating of Not Rated and set a new price target of $7.50

      4/12/21 11:57:17 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Financials

    Live finance-specific insights

    See more
    • Tiziana Life Sciences Announces Date of Annual General Meeting 2022

      NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that the 2022 Annual General Meeting of the Company will be held on December 29, 2022. The record date for voting at the Annual General Meeting is set as November 30, 2022. The notice, agenda and associated material have been despatched to shareholders via mail and the notice, agenda and related financial statements in the form of the relevant Form 20-F filing are available on the Company's website at https://ir.tizianalifesciences.com/shareholder-services/annual-ge

      12/6/22 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)

      NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a corporate update, including its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System (CNS) such as non-active secondary-progressive Multiple Sclerosis (SPMS), Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana, remarked, "We look forward to leveraging the exciting clinical and preclinical results from our

      11/10/22 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

      NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss its recently announced exclusive license agreement to evaluate Foralumab, the Company's novel, fully human anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T candidates for cancer treatment. Date:Wednesday, September 8, 2021  Time:4:15 p.m. Eastern Time  Live Call:+1-877-407-9716 (U.S. Toll-Free) or +1-201-493-6779 (International)

      9/7/21 2:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Leadership Updates

    Live Leadership Updates

    See more
    • Tiziana Life Sciences Appoints New Chief Executive Officer

      NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately. "We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences," said Gabriele Cerrone, Founder and Executive Chairman of the Board. " Ivor has an invaluable track record in creating substantial value for biotech and pharma companies with his strategic vision in building in

      8/19/24 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

      NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system, is being honored with the prestigious "Giants of MS" award for his outstanding contributions in the area of multiple sclerosis (MS) research. The award ceremony will take place on May 30, 2024 at the Consortium of Multipl

      5/30/24 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

      Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer. Dr. Clementi will formally take up the CDO role effective September 1, 2023. In this role, Dr. Clementi will be responsible for overseeing the company's development strategies and advancing its portfolio of groundbreaking therapeutic candidates. Dr. Clementi brings with

      8/23/23 10:30:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    SEC Filings

    See more
    • SEC Form 6-K filed by Tiziana Life Sciences Ltd.

      6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

      5/23/25 7:04:23 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Tiziana Life Sciences Ltd.

      6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

      5/15/25 8:00:09 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Tiziana Life Sciences Ltd.

      6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

      5/12/25 7:00:07 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tiziana Life Sciences Ltd.

      SC 13G - Tiziana Life Sciences Ltd (0001723069) (Subject)

      5/4/22 4:34:27 PM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Tiziana Life Sciences plc

      SC 13D - Tiziana Life Sciences Ltd (0001723069) (Subject)

      1/4/22 4:31:31 PM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Tiziana Life Sciences plc (0001723069) (Subject)

      2/16/21 7:32:16 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care